241 related articles for article (PubMed ID: 30154310)
1. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
Martínez-Jiménez C; Cruz-Angeles J; Videa M; Martínez LM
Molecules; 2018 Aug; 23(9):. PubMed ID: 30154310
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
Craye G; Löbmann K; Grohganz H; Rades T; Laitinen R
Molecules; 2015 Dec; 20(12):21532-48. PubMed ID: 26633346
[TBL] [Abstract][Full Text] [Related]
3. Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms.
Chen J; Li H; Li X; Yuan D; Cheng H; Ke Y; Cheng J; Wang Z; Chen J; Li J
Eur J Pharm Biopharm; 2022 Sep; 178():82-93. PubMed ID: 35932965
[TBL] [Abstract][Full Text] [Related]
4. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation.
Lodagekar A; Chavan RB; Mannava MKC; Yadav B; Chella N; Nangia AK; Shastri NR
Eur J Pharm Sci; 2019 Nov; 139():105048. PubMed ID: 31446077
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.
Khan FM; Ahmad M; Idrees HA
Drug Des Devel Ther; 2020; 14():4303-4313. PubMed ID: 33116417
[TBL] [Abstract][Full Text] [Related]
6. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
7. Co-solvent evaporation method for enhancement of solubility and dissolution rate of poorly aqueous soluble drug simvastatin: in vitro-in vivo evaluation.
Pandya P; Gattani S; Jain P; Khirwal L; Surana S
AAPS PharmSciTech; 2008; 9(4):1247-52. PubMed ID: 19115110
[TBL] [Abstract][Full Text] [Related]
8. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
9. Frozen in Time: Kinetically Stabilized Amorphous Solid Dispersions of Nifedipine Stable after a Quarter Century of Storage.
Theil F; Anantharaman S; Kyeremateng SO; van Lishaut H; Dreis-Kühne SH; Rosenberg J; Mägerlein M; Woehrle GH
Mol Pharm; 2017 Jan; 14(1):183-192. PubMed ID: 28043131
[TBL] [Abstract][Full Text] [Related]
10. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
11. Enhanced dissolution rate of simvastatin using spherical crystallization technique.
Varshosaz J; Tavakoli N; Salamat FA
Pharm Dev Technol; 2011 Oct; 16(5):529-35. PubMed ID: 20684739
[TBL] [Abstract][Full Text] [Related]
12. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
14. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions.
Löbmann K; Strachan C; Grohganz H; Rades T; Korhonen O; Laitinen R
Eur J Pharm Biopharm; 2012 May; 81(1):159-69. PubMed ID: 22353489
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
16. Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy.
Cruz-Angeles J; Videa M; Martínez LM
AAPS PharmSciTech; 2019 Mar; 20(4):144. PubMed ID: 30887140
[TBL] [Abstract][Full Text] [Related]
17. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
18. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
19. Extruded Soluplus/SIM as an oral delivery system: characterization, interactions, in vitro and in vivo evaluations.
Zhang Y; Liu Y; Luo Y; Yao Q; Zhong Y; Tian B; Tang X
Drug Deliv; 2016 Jul; 23(6):1902-11. PubMed ID: 25268150
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
